Michael Yee

UBS | Healthcare

Michael Yee is an analyst from UBS specializing in the Healthcare sector. Ranked #1113 out of 4535 analysts, they have issued 35 stock ratings with a success rate of 79.24% and an average return of 15.80%.

Michael Yee has a well-established track record, with 35 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 79.24% and an average return of 15.80%, underscoring their expertise and ability to identify winning opportunities for investors.

#1113

Out of 4535

35

Total Ratings

+79.24%

Success Rate

+15.80%

Average Return

Recent Ratings Analysis

ABBV

Feb 05, 2026

Target

$230.00

Current

$218.69

Performance

-0.15%

Michael Yee rated ABBV as Neutral on Feb 05, 2026, setting a price target of 230. The Hold stance appears justified, as shares hovered around 218.69 with a -0.15% move.

VRTX

Jan 26, 2026

Target

$545.00

Current

$458.81

Performance

-3.78%

On Jan 26, 2026, VRTX was given a Buy rating by Michael Yee, with a target price of 545. The stock traded sideways with a -3.78% move, keeping the bullish thesis unresolved.

GILD

Jan 26, 2026

Target

$155.00

Current

$149.37

Performance

8.41%

GILD received a Buy rating from Michael Yee on Jan 26, 2026, aiming for 155. Momentum has favored the Buy call, with shares climbing from 149.37 to 149.37, rewarding those who trusted the recommendation.

AMGN

Jan 26, 2026

Target

$390.00

Current

$367.80

Performance

5.18%

On Jan 26, 2026, Michael Yee published a Buy outlook on AMGN, with a target of 390. Shares gained 5.18%, underscoring the accuracy of the bullish outlook toward 390.

VTYX

Jan 08, 2026

Target

$20.00

Current

$13.94

Performance

0.72%

Michael Yee on Jan 08, 2026 assigned VTYX a Neutral rating, with a price target of 20. The Hold stance reflected consolidation, as shares held near 13.94.

ALGS

Jan 07, 2026

Target

$20.00

Current

$6.49

Performance

-32.75%

On Jan 07, 2026, Michael Yee reaffirmed ALGS with a Buy rating, targeting 20. Shares slid 32.75% despite the recommendation, highlighting downside risks.

ALLO

Jan 07, 2026

Target

$8.00

Current

$1.63

Performance

9.40%

ALLO was rated Buy by Michael Yee on Jan 07, 2026, with a price objective of 8. A bullish response from the market helped close the gap of 6.37 to the target.

BEAM

Jan 07, 2026

Target

$28.00

Current

$24.73

Performance

-14.52%

On Jan 07, 2026, Michael Yee initiated coverage on BEAM with a Neutral rating and target of 28. The rating matched the stock’s inability to hold above 24.73.

KOD

Jan 07, 2026

Target

$50.00

Current

$21.01

Performance

-22.39%

Michael Yee issued a Buy recommendation for KOD on Jan 07, 2026, price target set at 50. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

MBX

Jan 07, 2026

Target

$60.00

Current

$36.05

Performance

10.75%

On Jan 07, 2026, MBX was evaluated by Michael Yee, who gave a Buy rating and target of 60. This case illustrates how a timely bullish rating can translate into tangible gains of 10.75%.

NUVB

Jan 07, 2026

Target

$10.00

Current

$5.62

Performance

-36.43%

Michael Yee rated NUVB as Neutral on Jan 07, 2026, setting a price target of 10. The cautious Hold call aligned with subsequent weakness, as shares slipped 36.43%.

OLMA

Jan 07, 2026

Target

$45.00

Current

$25.01

Performance

-7.61%

On Jan 07, 2026, OLMA was given a Buy rating by Michael Yee, with a target price of 45. Despite the Buy call, shares fell from 25.01 to 25.01, challenging the optimistic stance.

SABS

Jan 07, 2026

Target

$7.00

Current

$3.98

Performance

0.25%

SABS received a Buy rating from Michael Yee on Jan 07, 2026, aiming for 7. Price action was muted, as shares hovered around 3.98 despite the bullish outlook.

SDGR

Jan 07, 2026

Target

$18.00

Current

$12.94

Performance

-31.06%

On Jan 07, 2026, Michael Yee published a Neutral outlook on SDGR, with a target of 18. Weakness in the stock, now at 12.94, supported the conservative rating.

SRRK

Jan 07, 2026

Target

$60.00

Current

$44.45

Performance

0.50%

Michael Yee on Jan 07, 2026 assigned SRRK a Buy rating, with a price target of 60. The recommendation remains pending validation as shares consolidate around 44.45.

VRDN

Jan 07, 2026

Target

$50.00

Current

$29.17

Performance

-4.58%

On Jan 07, 2026, Michael Yee reaffirmed VRDN with a Buy rating, targeting 50. Market indecision has kept the 50 target in a holding pattern.

ZLAB

Jan 07, 2026

Target

$35.00

Current

$16.98

Performance

-10.77%

ZLAB was rated Buy by Michael Yee on Jan 07, 2026, with a price objective of 35. This case shows how bullish projections can fail, with the stock now below 16.98.

ACLX

Jan 07, 2026

Target

$100.00

Current

$66.94

Performance

2.97%

On Jan 07, 2026, Michael Yee initiated coverage on ACLX with a Buy rating and target of 100. Neutral price movement of 2.97% leaves room for interpretation.

ANAB

Jan 07, 2026

Target

$70.00

Current

$47.90

Performance

5.95%

Michael Yee issued a Buy recommendation for ANAB on Jan 07, 2026, price target set at 70. Investors following the Buy call captured upside momentum, with shares now at 47.9.

DNLI

Jan 07, 2026

Target

$25.00

Current

$20.02

Performance

18.11%

On Jan 07, 2026, DNLI was evaluated by Michael Yee, who gave a Buy rating and target of 25. This case illustrates how a timely bullish rating can translate into tangible gains of 18.11%.

IDYA

Jan 07, 2026

Target

$50.00

Current

$31.77

Performance

-16.09%

Michael Yee rated IDYA as Buy on Jan 07, 2026, setting a price target of 50. The stock has underperformed, dropping 16.09% despite the bullish target of 50.

IMCR

Jan 07, 2026

Target

$55.00

Current

$30.92

Performance

-8.41%

On Jan 07, 2026, IMCR was given a Buy rating by Michael Yee, with a target price of 55. Despite the Buy call, shares fell from 30.92 to 30.92, challenging the optimistic stance.

IVA

Jan 07, 2026

Target

$12.00

Current

$5.80

Performance

13.73%

IVA received a Buy rating from Michael Yee on Jan 07, 2026, aiming for 12. Momentum has favored the Buy call, with shares climbing from 5.8 to 5.8, rewarding those who trusted the recommendation.

ORKA

Jan 07, 2026

Target

$50.00

Current

$31.42

Performance

12.98%

On Jan 07, 2026, Michael Yee published a Buy outlook on ORKA, with a target of 50. Shares gained 12.98%, underscoring the accuracy of the bullish outlook toward 50.

BIIB

Jan 07, 2026

Target

$185.00

Current

$185.36

Performance

-0.83%

Michael Yee on Jan 07, 2026 assigned BIIB a Neutral rating, with a price target of 185. The Hold stance reflected consolidation, as shares held near 185.36.

BMY

Jan 07, 2026

Target

$65.00

Current

$59.52

Performance

4.94%

On Jan 07, 2026, Michael Yee reaffirmed BMY with a Buy rating, targeting 65. Market indecision has kept the 65 target in a holding pattern.

LLY

Jan 07, 2026

Target

$1250.00

Current

$1020.46

Performance

-7.91%

LLY was rated Buy by Michael Yee on Jan 07, 2026, with a price objective of 1250. This case shows how bullish projections can fail, with the stock now below 1020.46.

PFE

Jan 07, 2026

Target

$25.00

Current

$26.49

Performance

4.79%

On Jan 07, 2026, Michael Yee initiated coverage on PFE with a Neutral rating and target of 25. The stock’s lack of movement around 26.49 aligned with a cautious approach.

CRGX

Jul 08, 2025

Target

$5.00

Current

$4.47

Performance

-2.40%

Michael Yee issued a Hold recommendation for CRGX on Jul 08, 2025, price target set at 5. The rating was appropriate for a consolidating market trading near 4.47.

BPMC

Mar 17, 2025

Target

$135.00

Current

$129.46

Performance

40.50%

On Mar 17, 2025, BPMC was evaluated by Michael Yee, who gave a Buy rating and target of 135. This case illustrates how a timely bullish rating can translate into tangible gains of 40.50%.

ALXO

Mar 06, 2025

Target

$3.00

Current

$2.06

Performance

57.25%

Michael Yee rated ALXO as Buy on Mar 06, 2025, setting a price target of 3. The call has proven timely, with shares rising 57.25% toward the price target of 3.

MRNA

Oct 15, 2024

Target

$55.00

Current

$40.87

Performance

-28.69%

On Oct 15, 2024, MRNA was given a Hold rating by Michael Yee, with a target price of 55. The rating provided protection from downside risk as the stock fell to 40.87.

AXON

Jul 17, 2024

Target

$385.00

Current

$399.65

Performance

25.76%

AXON received a Buy rating from Michael Yee on Jul 17, 2024, aiming for 385. Momentum has favored the Buy call, with shares climbing from 399.65 to 399.65, rewarding those who trusted the recommendation.

Frequency Asked Questions

Who is Michael Yee?

Michael Yee is an analyst from UBS specializing in the Healthcare sector.

What is Michael Yee's success rate?

Michael Yee currently has a success rate of +79.24%.

How many ratings has Michael Yee issued?

Michael Yee has issued 35 stock ratings so far.

What is the average return of Michael Yee's calls?

Their stock ratings have generated an average return of +15.80%.

What is Michael Yee's ranking?

Michael Yee is ranked #1113 out of 4535 analysts.

What types of ratings does Michael Yee give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Michael Yee?

You can follow Michael Yee by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Michael Yee?

Their latest rating was a Hold on ABBV issued on 2026-02-05.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep